Time Since Last Anti-CD20 Treatment Is a Major Determinant of Sars-Cov-2 Vaccine Response in a Large Cohort of Patients with B-Cell Lymphoma

Background: Patients with B-cell lymphoma have poor clinical outcomes to SARS-CoV-2 infection (COVID-19) and are also more likely to have suboptimal responses to immunization. An understanding of which lymphoma patients are at greatest risk of poor COVID-19 vaccine response and what aspects of immun...

Descripción completa

Detalles Bibliográficos
Autores principales: Shree, Tanaya, Shankar, Vishnu, Czerwinski, Debra K., Rodriguez, Gladys, Beygi, Sara, Schroers-Martin, Joseph G, Advani, Ranjana, Maeda, Lauren S., Gupta, Neel K., Khodadoust, Michael S., Kurtz, David M., Corbelli, Karen S., Gabriel, Etelka, Kanegai, Alyssa M., Alizadeh, Ash A., Levy, Ronald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology. Published by Elsevier Inc. 2021
Materias:
203.Lymphocytes and Acquired or Congenital Immunodeficiency Disorders
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701650/
http://dx.doi.org/10.1182/blood-2021-153901

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701650/
http://dx.doi.org/10.1182/blood-2021-153901

Ejemplares similares